JP2014531949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531949A5 JP2014531949A5 JP2014535059A JP2014535059A JP2014531949A5 JP 2014531949 A5 JP2014531949 A5 JP 2014531949A5 JP 2014535059 A JP2014535059 A JP 2014535059A JP 2014535059 A JP2014535059 A JP 2014535059A JP 2014531949 A5 JP2014531949 A5 JP 2014531949A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically active
- active compound
- exendin
- here
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 6
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
- 108010015174 exendin 3 Proteins 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11185135 | 2011-10-14 | ||
| EP11185135.8 | 2011-10-14 | ||
| PCT/EP2012/070099 WO2013053781A1 (en) | 2011-10-14 | 2012-10-11 | Assembly for a drug delivery device |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531949A JP2014531949A (ja) | 2014-12-04 |
| JP2014531949A5 true JP2014531949A5 (enExample) | 2015-11-26 |
| JP6290087B2 JP6290087B2 (ja) | 2018-03-07 |
Family
ID=47008605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535059A Active JP6290087B2 (ja) | 2011-10-14 | 2012-10-11 | 薬物送達デバイスのアセンブリ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9687614B2 (enExample) |
| EP (1) | EP2766072B1 (enExample) |
| JP (1) | JP6290087B2 (enExample) |
| CN (1) | CN103998082B (enExample) |
| DK (1) | DK2766072T3 (enExample) |
| TR (1) | TR201902465T4 (enExample) |
| WO (1) | WO2013053781A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10576207B2 (en) | 2015-10-09 | 2020-03-03 | West Pharma. Services IL, Ltd. | Angled syringe patch injector |
| JP7017512B2 (ja) * | 2015-10-09 | 2022-02-08 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 充填済流体容器の屈曲流体路型付属物 |
| JP6885960B2 (ja) | 2016-01-21 | 2021-06-16 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 視覚的インジケータを有する薬剤デリバリデバイス |
| WO2018076341A1 (zh) * | 2016-10-31 | 2018-05-03 | 创新精密仪器有限公司 | 重置机构及其药物输送装置 |
| GB201721065D0 (en) * | 2017-12-15 | 2018-01-31 | Ondosis Ab | Delivery device for drug pellets |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8713810D0 (en) * | 1987-06-12 | 1987-07-15 | Hypoguard Uk Ltd | Measured dose dispensing device |
| US6221053B1 (en) * | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
| DE102005019428A1 (de) * | 2005-04-25 | 2006-10-26 | Tecpharma Licensing Ag | Längenausgleich für eine Einstellvorrichtung einer Injektionsvorrichtung |
| EP1923083A1 (en) | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Drive mechanisms for use in drug delivery devices |
| DE102007026083A1 (de) * | 2007-05-25 | 2008-11-27 | Haselmeier S.A.R.L. | Injektionsgerät |
| SI2274029T1 (sl) | 2008-05-02 | 2012-03-30 | Sanofi Aventis Deutschland | Naprava za dovajanje zdravila |
| JP5748738B2 (ja) * | 2009-03-31 | 2015-07-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイス |
| US8568141B2 (en) | 2009-06-26 | 2013-10-29 | Showa Yakuhin Kako Co., Ltd. | Linearly motorized dental syringe |
| AR079004A1 (es) * | 2009-09-30 | 2011-12-21 | Sanofi Aventis Deutschland | Dispositivo de dispensacion de farmacos |
| AR078458A1 (es) * | 2009-09-30 | 2011-11-09 | Sanofi Aventis Deutschland | Conjunto de accionamiento, vastago de piston, dispositivo para la entrega de drogas, y uso de un resorte |
| CA2790283A1 (en) * | 2010-02-22 | 2011-08-25 | Sanofi-Aventis Deutschland Gmbh | Force transmission arrangement for auto-injector |
-
2012
- 2012-10-11 JP JP2014535059A patent/JP6290087B2/ja active Active
- 2012-10-11 DK DK12770131.6T patent/DK2766072T3/en active
- 2012-10-11 WO PCT/EP2012/070099 patent/WO2013053781A1/en not_active Ceased
- 2012-10-11 US US14/350,573 patent/US9687614B2/en active Active
- 2012-10-11 EP EP12770131.6A patent/EP2766072B1/en active Active
- 2012-10-11 CN CN201280061659.7A patent/CN103998082B/zh active Active
- 2012-10-11 TR TR2019/02465T patent/TR201902465T4/tr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516700A5 (enExample) | ||
| JP2014519900A5 (enExample) | ||
| JP2014516702A5 (enExample) | ||
| JP2014516701A5 (enExample) | ||
| JP2014527887A5 (enExample) | ||
| JP2014531949A5 (enExample) | ||
| Moscona | Medical management of influenza infection | |
| Poole et al. | Ipragliflozin: first global approval | |
| CN114901681A (zh) | 胰岛素衍生物 | |
| CN115916772A (zh) | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2010515677A5 (enExample) | ||
| EA201692282A1 (ru) | Композиция для лечения сахарного диабета, содержащая инсулин и двойной агонист glp-1/глюкагона | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| JP2012505852A5 (enExample) | ||
| JP2014520798A5 (enExample) | ||
| JP2012512907A5 (enExample) | ||
| JP2013533268A5 (enExample) | ||
| CN109906077A (zh) | 依达拉奉与(+)-2-莰醇的舌下用药物组合物 | |
| JP2012520866A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| JP2014532722A5 (enExample) | ||
| JP2020510628A5 (enExample) | ||
| Wan et al. | Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the Nanopatch™ microprojection array | |
| WO2007124700A3 (en) | Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof | |
| Paccaly et al. | Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects |